News

We are thrilled to have participated in the Move for Tourette’s 2024 challenge! Our team completed a 10K walk around the beautiful Wollaton Park in Nottingham, all in support of @Tourettes Action.

We were honoured to be nominated in four highly competitive categories showcasing the incredible talent and innovation thriving in the region.

The categories nominated include Innovation, One to watch, Partnership between Academia and business and Outstanding Achievement.

Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialisation. 

Neupulse has been awarded the prestigious Science, Technology, Engineering and Maths Research Project of the Year at the Times Higher Education Awards 2023!

Neupulse is excited to share the success of TICfest, a heartwarming event organised by Tourettes Action that brought together individuals with Tourette Syndrome and their families. It was a day of connection, learning and community.

We're excited to announce that Neupulse’s groundbreaking medical device has been shortlisted for the Science, Technology, Engineering and Maths (STEM) Research Project of the Year at the 2023 Times Higher Education (THE) Awards.

We are thrilled to share that Neupulse had the opportunity to be a part of Aidy Smith's radio documentary, "Tourette's: The Truth Behind the Tics"

During his talk, Professor Jackson gave the background into using the peripheral nervous system to stimulate the brain to reduce the urge to tic and tic frequency

Watch a clip taken from Channel 5's Documentary 'Teacher with Tourette's' featuring the Neupulse device

Neupulse is delighted to welcome two new members to our team: Ciara McCready as a Research Assistant and Claire Hall as our Quality & Regulatory Manager.

We are excited to share the results of the UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome.

Neupulse is excited to announce that it has recruited 2 new key executives to their senior management team.

What an incredible morning! Our team at Neupulse was honored to host Lewis Capaldi, who came to visit us in Nottingham to try out our wearable device for treating Tourette Syndrome.

Neupulse has completed a second round of funding in December 2022 of £918k. Funds have been raised from existing investors and groups of HNW individuals from around the world

Will Tourette's ever be curable? Brain-altering gadget that stops involuntary tics could prove life-changing, doctors hope as Lewis Capaldi reveals he has the 'uncomfortable' syndrome

Following the program “Britain’s Tourette’s Mystery” that was aired on C4 last week which contained many inaccurate and misleading facts, Tourette’s Action UK has issues the following press release

The presentation gave the background into using the peripheral nervous system to stimulate the brain to reduce the urge to tic and tic frequency.

BBC Presenter, Aidy Smith tried Median Nerve Stimulation and was amazed at the positive impact it had on his urge to tic and gave him a very relaxed feeling with no tics. 

A wearable wrist device that delivers electrical pulses to reduce the amount and severity of tics experienced by individuals with Tourette Syndrome (TS) is being tested in a UK-wide clinical trial.

Recent publications from the Neurotherapeutics team

Professor Stephen Jackson has been invited to deliver 2 Keynote addresses in the coming months describing the Neurotherapeutics Ltd approach to suppressing tics in Tourette syndrome

We are happy to report that an application to establish the NeuroMod+ research network was successfully funded by the EPSRC

Neurotherapeutics Ltd have now produced 80 prototype wearable medical devices for use in a UK-wide randomised double-blind placebo-controlled trial investigating the efficacy of rhythmic median nerve stimulation in suppressing the urge-to-tic in Tourette syndrome.

Neurotherapeutics won the ‘One to watch’ award with Professor Stephen and Georgina Jackson accepting the award.

Professor Stephen Jackson was Recently appointed Chair of the Scientific Advisory Board for the Federation of European Societies for Neuropsychology (FESN).

Neurotherapeutics Ltd received MHRA approval to use prototype clinical investigation devices in a new clinical study which will start in March 2022.

Neurotherapeutics Ltd has been shortlisted in 3 categories for these prestigious awards which recognises and promotes the excellence that East and West Midlands companies are achieving at the leading edge of the Life Sciences sector.